BTIG raised the firm’s price target on Praxis Precision (PRAX) to $499 from $424 and keeps a Buy rating on the shares. The firm also names the stock its Top Pick for 2026. The positive pre-NDA meeting and receipt of written feedback from the FDA aligns Praxis with the Agency on the content of its NDA for ulixa in ET that will be submitted in early 2026, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRAX:
- Praxis Precision price target raised to $340 from $258 at H.C. Wainwright
- Closing Bell Movers: Rubrik up 14% on earnings beat; Oklo down on $1.5B offering
- Praxis Precision announces results from EMBOLD study cohort
- Praxis Precision completes pre-NDA meeting with FDA
- 3 ‘Strong Buy’ Stocks to Buy Today, 12/4/2025, According to Top Analysts